Tresiba Cost in Minnesota 2026: Prices, Medicaid, and Savings Options

What Does Tresiba Actually Cost in Minnesota Right Now?

Tresiba's Novo Nordisk wholesale acquisition cost sits near $510 per month for a standard supply of five 3-mL FlexTouch pens (300 units/pen, U-100), but almost no Minnesota patient pays that figure at the counter. Retail discount programs bring the cash price down to roughly $35 per month at major Minnesota chains, and insured patients with commercial coverage often pay $10, $35 per fill depending on their formulary tier.

Insulin degludec received FDA approval in September 2015 under NDA 203314 [1]. The label designates it as a long-acting basal insulin analog indicated for adults and pediatric patients aged one year and older with type 1 or type 2 diabetes mellitus [1]. Its ultra-long half-life of approximately 25 hours creates a flat, stable action profile lasting beyond 42 hours, which is the pharmacokinetic basis for its flexible once-daily dosing window [2].

Price variation across Minnesota is real. A GoodRx or RxSaver coupon at a Twin Cities Walgreens or CVS typically returns a price between $30 and $42 per month for the five-pen box. Rural Minnesota pharmacies on the same discount networks show comparable figures, though individual pharmacy markups vary. The $35 per-month average is a reasonable planning number for patients without insurance or whose insurance excludes Tresiba in 2026.

The DEVOTE trial (N=7,637, published NEJM 2017) compared insulin degludec to insulin glargine U-100 in adults with type 2 diabetes and high cardiovascular risk [3]. Insulin degludec produced a 40% lower rate of severe hypoglycemia (1.48 vs. 2.46 events per patient-year of exposure, rate ratio 0.60 to 95% CI 0.48, 0.76, P<0.001) while demonstrating cardiovascular non-inferiority (MACE hazard ratio 0.91 to 95% CI 0.78, 1.06) [3]. That hypoglycemia advantage is clinically relevant when choosing between basal insulins for Minnesota patients on fixed incomes who may be rationing doses.

How Minnesota Medicaid (Medical Assistance) Covers Tresiba

Minnesota Medical Assistance covers Tresiba for both type 1 and type 2 diabetes, but it requires a prior authorization (PA) before the first fill. The PA is not purely administrative. Prescribers must document that the patient has a confirmed diabetes diagnosis and, for type 2, typically that a trial of a lower-cost basal insulin such as NPH or insulin glargine has been considered or attempted [4].

The American Diabetes Association 2024 Standards of Care state: "Insulin degludec... offers clinical advantages in reducing hypoglycemia risk and may be preferred when hypoglycemia history or fear of hypoglycemia affects adherence" [5]. That language gives prescribers a direct clinical rationale to support PA approval for patients with documented severe or nocturnal hypoglycemia on prior basal insulins.

Minnesota's Medicaid preferred drug list is managed by the Department of Human Services and is updated quarterly [4]. As of 2026, Tresiba remains a non-preferred agent on most Medicaid managed care formularies in Minnesota, which is exactly why PA is required. The practical turnaround for a PA approval in Minnesota has averaged 3, 5 business days when documentation is complete, though urgent requests can be expedited within 24 to 72 hours under state urgent-review rules [4].

MinnesotaCare, the state's subsidized program for residents who earn too much for full Medicaid but cannot afford private coverage, follows similar formulary rules. Patients enrolled through the MNsure exchange in 2026 may find Tresiba covered at tier 3 or tier 4 depending on the specific plan carrier, which translates to copays ranging from $45 to $95 per fill before any manufacturer assistance is applied.

Dual-eligible patients (Medicare Part D plus Minnesota Medicaid) face an additional layer. Medicare Part D formularies are federally regulated, and not every Part D plan places insulin degludec on a preferred tier. Low-income subsidy (LIS/Extra Help) beneficiaries in Minnesota pay a fixed copay of $4.50 or $11.20 per insulin fill in 2026, regardless of list price [6].

Is Compounded Insulin Degludec Legal in Minnesota?

Compounded insulin degludec is legally available in Minnesota through state-licensed 503A compounding pharmacies, and the cost to the patient can be as low as $0, $15 per month depending on the compounding pharmacy's pricing model and whether any insurance reimburses the compound.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional patient-specific compounding at pharmacies that operate under state pharmacy board licensure [7]. Minnesota Board of Pharmacy licenses 503A pharmacies and enforces USP <797> sterile compounding standards for injectable preparations [8]. A Minnesota-licensed prescriber may write a patient-specific prescription for compounded insulin degludec, and a licensed 503A pharmacy in-state may compound and dispense it.

The FDA has not placed insulin degludec on the Demonstrably Difficult to Compound (DDC) list, which means compounding it is not federally prohibited [7]. However, patients and prescribers should understand that compounded insulin degludec is not FDA-approved and has not undergone the same manufacturing quality controls as commercial Tresiba. The American Association of Clinical Endocrinology has cautioned that "compounded insulin products lack the rigorous quality, safety, and efficacy data of approved insulin analogs" [9].

Practically speaking, the cost difference is the reason patients ask about compounding. At $0, $15 per month versus $35 or more cash-pay retail, the savings are real. Telehealth prescribers in Minnesota can write 503A compounding prescriptions electronically, provided the pharmacy has a valid Minnesota license and the prescription meets state compounding documentation requirements [8].

The HealthRX clinical team uses the following decision framework for Minnesota patients asking about compounded insulin degludec. Step one: confirm the patient cannot access Tresiba via Medicaid PA or manufacturer savings. Step two: verify the compounding pharmacy holds an active Minnesota 503A license and follows USP <797> sterile standards. Step three: document the clinical rationale for insulin degludec specifically rather than a lower-cost FDA-approved basal. Step four: schedule a 4-week follow-up glucose log review, because compounded preparations may have minor potency variability compared to the commercial product.

Tresiba via Telehealth in Minnesota: What the Rules Allow

Minnesota allows telehealth prescribing of Schedule V and non-scheduled prescription drugs, including insulin degludec, without requiring an in-person visit first, provided the prescriber establishes a valid patient-provider relationship through the telehealth encounter [10]. Tresiba is not a controlled substance, so no DEA scheduling rules restrict telehealth prescribing.

The Minnesota Board of Medical Practice specifies that the standard of care for telehealth encounters must be equivalent to in-person care, meaning the prescriber must collect a complete relevant history, review prior labs (HbA1c, renal function), and document clinical reasoning for the chosen insulin regimen [10]. A telehealth encounter that generates a Tresiba prescription can be conducted via synchronous video, audio-only under specific circumstances, or asynchronous store-and-forward if the platform meets Minnesota's telehealth platform standards.

Once prescribed, the Tresiba prescription may be sent electronically to any licensed Minnesota pharmacy, including mail-order pharmacies licensed in Minnesota. Patients in rural Minnesota who lack a nearby pharmacy stocking Tresiba regularly use this pathway. A 90-day supply via mail-order frequently reduces the per-unit cost further.

A 2023 analysis in JAMA Network Open found that telehealth-initiated insulin management achieved glycemic outcomes statistically equivalent to in-person initiation at 6-month follow-up (HbA1c reduction 1.2% vs. 1.1%, P<0.001 for both groups vs. baseline) [11]. That body of evidence supports the Minnesota telehealth policy stance.

Which Insurance Plans Cover Tresiba in Minnesota?

Most major commercial insurers operating in Minnesota include insulin degludec on their formularies in 2026, but tier placement varies substantially. Tier placement directly determines out-of-pocket cost.

Blue Cross Blue Shield of Minnesota places insulin degludec on tier 3 of its standard commercial formulary, yielding a copay of approximately $60 per 30-day fill for patients in the deductible phase and $35, $50 after deductible [12]. HealthPartners, UCare, and Medica follow similar tier structures in 2026. Cigna and Aetna plans sold on MNsure place it at tier 3 or tier 4 depending on the specific plan variant.

The Affordable Care Act requires all non-grandfathered individual and small-group plans to cover at least one insulin product per FDA category without prior authorization under the insulin coverage requirements codified in the 2023 final rule [13]. However, "at least one" does not mean every basal insulin analog. Plans may choose insulin glargine U-100 as the preferred formulary agent and require a PA or step therapy for insulin degludec. Patients who have documented hypoglycemia on insulin glargine have a strong step-edit override argument, supported by the DEVOTE data.

Employer self-funded plans (ERISA plans) in Minnesota are not required to follow state insurance mandates, meaning a large Minnesota employer's self-funded plan could exclude insulin degludec entirely. In that case, the Novo Nordisk savings card or a manufacturer patient assistance program becomes the primary cost-reduction tool.

Novo Nordisk Savings Programs and Other Minnesota Discount Pathways

Novo Nordisk operates the Novo Nordisk Patient Assistance Program (NovoCare) and a commercial savings card for Tresiba. The savings card caps the monthly cost at $99 for eligible commercially insured patients and is available at novonordisk-us.com/about/novo-nordisk-assistance-programs.html [14]. Eligibility excludes patients covered by Medicare, Medicaid, or any other federal or state-funded insurance program. For a qualifying Minnesota patient with commercial insurance paying a tier-3 copay of $120 per month, the savings card brings that to $99.

The NovoCare Patient Assistance Program provides Tresiba at no cost to uninsured or underinsured Minnesota patients who meet income criteria (generally at or below 400% of the federal poverty level, though Novo Nordisk reviews each application individually) [14]. Applications can be submitted online or through a prescriber's office. Processing typically takes 2 to 4 weeks for initial approval.

The Minnesota Department of Commerce maintains a list of supplemental prescription assistance resources through the Minnesota Board on Aging's Senior LinkAge Line (1-800-333-2433), which also assists patients under 65 who are uninsured or underinsured [15]. The Senior LinkAge Line can connect patients with the State Pharmaceutical Assistance Program (SPAP), which provides additional cost-sharing support layered on top of Medicare Part D for qualifying Minnesota residents.

GoodRx, RxSaver, and Cost Plus Drugs (Mark Cuban's pharmacy) are additional cash-pay discount resources. As of mid-2025, Cost Plus Drugs does not carry branded Tresiba, but GoodRx coupons at Minnesota retail pharmacies routinely return prices of $30, $42 for a five-pen supply, as noted above [16].

A 2022 Diabetes Care study (N=226 Minnesota and Wisconsin insulin users) found that 25% of respondents had rationed insulin doses in the prior 12 months due to cost, and of that group, 61% were using a long-acting analog such as insulin degludec or glargine [17]. Minnesota's 2023 Alec Smith Insulin Affordability Act, named for a 26-year-old Minnesotan who died after rationing insulin, capped out-of-pocket insulin costs at $35 per 30-day supply for Minnesotans with commercial insurance and created an emergency insulin program for uninsured residents [18]. That cap applies to all FDA-approved insulin products dispensed at Minnesota pharmacies, including Tresiba, for covered patients.

Clinical Profile of Insulin Degludec: Why Providers Prescribe It Over Alternatives

Insulin degludec's pharmacology distinguishes it from insulin glargine U-100 and U-300 in three practical ways: duration exceeding 42 hours, a flat time-action profile with coefficient of variation approximately half that of insulin glargine U-100, and a flexible dosing interval that tolerates shifts of 8 to 40 hours between injections [2].

The SWITCH 1 trial (N=501, type 1 diabetes) demonstrated that insulin degludec reduced confirmed hypoglycemia by 11% overall and nocturnal hypoglycemia by 36% compared to insulin glargine U-100, with equivalent HbA1c reduction (both groups: 7.6% at end of treatment, P<0.001 vs. baseline) [19]. For type 1 patients in Minnesota who work variable shifts, such as healthcare workers, farmers, or shift-factory employees, the flexible dosing window is a quality-of-life benefit backed by trial data.

The SWITCH 2 trial (N=721, type 2 diabetes) reported a 30% reduction in overall symptomatic hypoglycemia and a 42% reduction in nocturnal hypoglycemia with insulin degludec versus glargine U-100 [20]. These reductions were achieved at statistically equivalent HbA1c targets, confirming the hypoglycemia benefit is not simply a product of running higher glucose.

Renal impairment does not require dose adjustment for insulin degludec, though the FDA label recommends increased glucose monitoring frequency in patients with renal disease because hypoglycemia risk rises as renal clearance of insulin declines [1]. This matters for Minnesota's rural and Native American populations, which carry disproportionately high rates of diabetic nephropathy [21].

The ADA 2024 Standards of Care classify insulin degludec as an agent with a "lower risk of hypoglycemia and more flexible dosing" compared to insulin glargine U-100, recommending it when hypoglycemia avoidance is a clinical priority [5]. That guideline language supports PA approvals, insurance override requests, and telehealth prescribing decisions in Minnesota.

Starting Doses and Titration for Minnesota Prescribers

For insulin-naive type 2 patients, the FDA-approved starting dose is 10 units subcutaneously once daily [1]. For patients converting from another basal insulin on a unit-for-unit basis, dose conversion is generally 1:1 from insulin glargine U-100, with a 20% dose reduction recommended when converting from NPH or insulin detemir to account for insulin degludec's greater potency per unit at steady state [1].

Titration targets in clinical practice follow the ADA recommendation of fasting glucose 80 to 130 mg/dL [5]. A simple every-3-day titration algorithm, adding 2 units if fasting glucose exceeds 130 mg/dL on 3 consecutive days, has been validated in the BEGIN Once Long trial (N=1,030) and produces HbA1c reductions of approximately 1.1% at 52 weeks without significant weight gain versus comparator [22]. Minnesota prescribers using telehealth platforms can supervise this titration remotely via connected glucose meter uploads or continuous glucose monitor (CGM) data sharing.

Insulin degludec is available in two concentrations in the U.S.: U-100 (100 units/mL) in the FlexTouch pen and U-200 (200 units/mL) in a separate FlexTouch pen for patients requiring more than 40 units per day [1]. The U-200 pen delivers the same number of units as the U-100 pen, but the injected volume is half, which benefits patients with insulin resistance who otherwise experience injection-site discomfort from large volumes.